(Q43807549)

27 November 2017

title

Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer (English)

1 reference

27 November 2017

1 reference

Fredstorp-Lidebring M

1

1 reference

27 November 2017

Bendahl PO

2

1 reference

27 November 2017

Brünner N

3

1 reference

27 November 2017

Casslén B

4

1 reference

27 November 2017

Högberg T

5

1 reference

27 November 2017

Långström-Einarsson E

6

1 reference

27 November 2017

Willén R

7

1 reference

27 November 2017

Fernö M

8

1 reference

27 November 2017

publication date

1 December 2001

1 reference

European Journal of Cancer

27 November 2017

published in

1 reference

27 November 2017

volume

37

1 reference

27 November 2017

issue

18

1 reference

27 November 2017

page(s)

2339-2348

1 reference

Prognostic factors in endometrial cancer

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

Indications for adjuvant radiotherapy in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

The urokinase-type plasminogen activator system in cancer metastasis: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

The plasminogen activator urokinase and its inhibitor PAI-2 in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

Plasminogen activator inhibitors in endometrial adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

Tumor-associated proteolytic factors uPA and PAI-1 in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

The concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

Discordant expression of mRNA and protein for urokinase and tissue plasminogen activators (u-PA, t-PA) in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

Flow-cytometric DNA analysis in primary breast carcinomas and clinicopathological correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

Statistical evaluation of cell kinetic data from DNA flow cytometry (FCM) by the EM algorithm

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

Identification of TP53 gene mutations in uterine corpus cancer with short follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

Statistical aspects of prognostic factor studies in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

The Prognostic Information of DNA Ploidy and S-PHASE Fraction May Vary with Histologic Grade in Endometrial Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

Flow cytometric deoxyribonucleic acid index: a prognostic factor in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

Flow cytometric measurements of DNA index and S-phase on paraffin-embedded early stage endometrial cancer: an important prognostic indicator

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

DNA ploidy, morphometry, and nuclear grade as prognostic factors in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

Time-dependence of hazard ratios for prognostic factors in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

An analysis of approaches to the treatment of endometrial cancer in Western Europe: A CTF study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

An Analysis of Approaches to the Management of Endometrial Cancer in North America: A CTF Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900306-9

7 January 2021

10.1016/S0959-8049(01)00306-9

Identifiers

DOI

1 reference

27 November 2017

1 reference